Factor IX gene therapy - Avigen
Alternative Names: Coagulin B; Haemophilia B gene therapyLatest Information Update: 25 Sep 2021
At a glance
- Originator Avigen
- Class Blood coagulation factors; Coagulants; Gene therapies
- Mechanism of Action Factor IX stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Haemophilia B
Most Recent Events
- 27 Jun 2005 Discontinued - Phase-I for Haemophilia B in USA (IM)
- 27 Jun 2005 Discontinued - Phase-I/II for Haemophilia B in USA (Intrahepatic)
- 23 Jun 2005 Data presented at the 8th Annual Meeting of the American Society of Gene Therapy (ASGT-2005) have been added to the Haematological disorders pharmacodynamics section